17R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
FILSPARI Growth And AdoptionRapid FILSPARI sales growth and expanding patient starts indicate strong product adoption across IgA nephropathy and FSGS. Continued uptake can broaden Travere’s commercial base, improve operating leverage, and provide a durable revenue foundation as both indications mature.
Improving Profitability And Cash GenerationThe combination of very high gross margins, positive operating cash flow, and slightly positive EBITDA shows meaningful progress toward a self-funding commercial model. If sustained, this improvement can support pipeline investment and reduce reliance on external financing over the coming quarters.
Differentiated Product And Pipeline DepthClinical differentiation for FILSPARI and continued investment in rare kidney disease candidates strengthen Travere’s strategic position beyond a single marketed asset. Sustained evidence generation and pipeline expansion could extend growth opportunities and reinforce physician and payer confidence.
Bears Say
Very High LeverageThe sharply reduced equity cushion leaves Travere highly exposed to operating setbacks, refinancing needs, and financing costs. Even with improving commercial performance, this capital structure can constrain strategic flexibility and divert future cash generation toward debt obligations rather than growth.
Profitability Remains UnprovenTravere has not yet converted revenue scale into durable bottom-line or operating profitability. Persistently high operating investment, including spending behind FSGS and Phase III programs, may keep cash conversion limited and prolong dependence on successful execution and financing access.
Gross-to-net PressureHigher discounts reduce the revenue retained from each FILSPARI prescription and can temper the earnings benefit of strong demand growth. The expected pressure in the second half indicates that indication mix and reimbursement dynamics may weigh on commercial margins as FSGS adoption expands.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is CHF4.15B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Oct 22, 2026 which is in 6 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Aug 04, 2026. The company reported -CHF0.306 earnings per share for the quarter, missing the consensus estimate of -CHF0.112 by -CHF0.194.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is 0.02.
How many shares outstanding does Travere Therapeutics have?
Currently, no data Available
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -CHF0.306 in its last earnings report, missing expectations of -CHF0.112. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in CH:17R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF62.98 (― Upside)
CHF62.98 (― Upside)
Blogger Sentiment
Neutral
CH:17R Sentiment 56%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.61%
12-Months-Change
Fundamentals
Return on Equity
-55.79%
Trailing 12-Months
Asset Growth
43.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
17R Company Deck
17R Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and a positive growth trajectory: record FILSPARI demand and revenue, an encouraging FSGS launch that outpaced early IgA nephropathy uptake, meaningful pipeline additions (pegtibatinase and civorebrutinib), an IP allowance for IgAN methods, and a reinforced balance sheet following convertible refinancing. Offsetting items include elevated operating expenses, a $40M inducement expense, a $112.5M upfront payment for civorebrutinib (post-quarter), expected higher gross-to-net discounts in H2, and limited disclosure of granular commercial metrics and FSGS-specific IP outcomes. On balance, the strengths and growth drivers substantially outweigh the near-term costs and disclosure gaps reported in the quarter.View all CH:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
―Ionis Pharmaceuticals
―
Omeros
―
Aurinia Pharmaceuticals
―
Immunovant
―
Vera Therapeutics
―